Does Methylphenidate Work in Children and Adolescents with Attention Deficit Hyperactivity Disorder?
Johanne Pereira Ribeiro1, Emma Jasmine Arthur1, Christian Gluud2,3
1Center for Evidence-Based Psychiatry, Psychiatric Research Unit, Psychiatry Region Zealand, 4200 Slagelse, Denmark.
Pediatric Reports
|August 27, 2021
Summary
Evidence for methylphenidate
Area of Science:
- Child and Adolescent Psychiatry
- Pharmacology
- Evidence Synthesis
Background:
- Attention deficit hyperactivity disorder (ADHD) is a prevalent neurodevelopmental disorder in children and adolescents.
- Methylphenidate has been a primary pharmacological treatment for ADHD for over six decades.
- Recent research prompts a re-evaluation of methylphenidate's efficacy and safety.
Purpose of the Study:
- To provide an overview of methylphenidate's effects in children and adolescents with ADHD.
- To synthesize current evidence, prompted by a notable Cochrane review.
- To assess the quality of existing research on methylphenidate for ADHD.
Main Methods:
- Systematic search for systematic reviews and meta-analyses on methylphenidate for ADHD.
- Inclusion of studies comparing methylphenidate to placebo or no treatment.
- Quality assessment of included studies using AMSTAR II criteria.
Main Results:
- Identified 24 eligible systematic reviews and meta-analyses; 11 deemed high-quality.
- The certainty of evidence supporting methylphenidate's benefits for ADHD in youth is very low.
- Underreporting of adverse events may obscure the true benefit-harm balance.
Conclusions:
- Group-level evidence for methylphenidate's benefit in treating pediatric ADHD remains uncertain.
- Future research should utilize individual participant data for comprehensive analysis.
- Further studies should explore intervention effects across various patient modifiers (age, sex, subtype, comorbidities, dose).
More Related Videos
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
5.9K
13:09Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol
Published on: April 1, 2018
10.5K
Related Concept Videos
01:30Attention-Deficit/Hyperactivity Disorder
443
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
443
01:28Adrenergic Agonists: Mixed-Action Agents
1.1K
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
1.1K
01:30Adrenergic Agonists: Therapeutic Uses
1.2K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
1.2K
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.5K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.5K
01:24Antiasthma Drugs: Methylxanthines
616
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
616
01:25Adrenergic Agonists: Indirect-Acting Agents
2.1K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.1K